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We report the ﬁrst case of epidermal-growth-factor-receptor (EGFR) mutation-positive lung
adenocarcinoma with acrometastasis in a 51-year-old woman who presented with a swelling on
her right hand. Magnetic resonance imaging revealed an expansile lesion at the base of the 5th
metacarpal bone of her right hand with cortical erosion and patchy enhancement suggestive of
a malignant transformation of a giant-cell tumor. A core needle biopsy of this lesion showed a
metastatic adenocarcinoma on histopathological examination which was immunoreactive to
cytokeratin (CK) 7 and thyroid transcription factor (TTF)-1 but not to CK20 suggesting a lung
primary. A chest radiograph and computed tomography (CT) scan revealed a right upper lobe
lung mass. Fluoro-deoxyglucose hypermetabolism was noted in the lung mass and the right 5th
metacarpal bone lesion but not elsewhere on positron-emission-tomography/CT scan. Needle
biopsy of the lung mass showed adenocarcinoma with histopathological and immunohistochem-
ical features similar to that of the right 5th metacarpal bone lesion. Both the primary lung
adenocarcinoma and the acrometastatic lesion were tested positive for EGFR mutation in exon
21 (L858R substitution). She underwent R0 resection of her right upper and middle lobes with
systematic mediastinal lymph nodes resection and wide excision of the metacarpal metastasis
followed by cytotoxic chemotherapy. A curative approach with complete resection of the
primary tumor and oligometastastic site in Stage IV non-small cell lung carcinoma (NSCLC)
followed by additive cytotoxic chemotherapy has not been reported to date and as such there is
still no data on disease-free survival with this approach.
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Fig. 1 Photograph of the swelling on the dorsum of the
right hand.
Fig. 2 Radiograph of the right hand shows an expansile lesion
at the base of the 5th metacarpal bone.
M.-E. Poh et al.221. Introduction
While acrometastasis to the hands is uncommon, the lung
remains the most common primary [1]. Acrometastasis from
an epidermal-growth-factor-receptor (EGFR) mutant lung
adenocarcinoma has not been reported to date.
2. Case report
A 51-year-old woman who had never smoked presented to us
with a 6-month history of a swelling on the dorsum of her right
hand (Fig. 1). A radiograph (Fig. 2) and a magnetic resonance
imaging (MRI) of her right hand at another hospital revealed an
expansile lytic lesion at the base of the 5th metacarpal bone
with cortical erosion suggestive of a malignant transformation
of a giant-cell tumor. She was then referred to us. A trucut core
needle biopsy of the 5th metacarpal bone lesion revealed
poorly differentiated adenocarcinoma which was immunoreac-
tive to cytokeratin (CK)-7 and thyroid transcription factor
(TTF)-1 but not to CK20 suggesting a lung primary. Computed
tomography (CT) scan revealed a right upper lobe lung mass
measuring 2.3 2.5 3.8 cm3 (Fig. 3). A positron emission
tomography (PET)/CT scan revealed ﬂuoro-deoxyglucose hyper-
metabolism in the lung lesion and the right 5th metacarpal
bone lesion but not elsewhere. Core needle biopsy of the lung
lesion showed adenocarcinoma with histopathological and
immunohistochemical features similar to that of the right 5th
metacarpal bone lesion. Both the primary lung and the
acrometastatic lesions were tested positive for EGFR L858R
substitution mutation in exon 21. She underwent complete (R0)
resection of the right upper and middle lobes with systematic
mediastinal lymph nodes resection and a wide excision of the
right 5th metacarpal bone albeit a stage IV disease. Post-
operative pathological stage was pT2N0M1b R0. She underwent
four cycles of cytotoxic chemotherapy with carboplatin and
vinorelbine as she could not ﬁnancially afford EGFR-tyrosine
kinase inhibitor (TKI) treatment. A post-treatment PET/CT scan
eight months later showed no ﬂuoro-deoxyglucose hypermeta-
bolism suggestive of any locoregional recurrence or distant
metastasis.
3. Discussion
Acrometastasis to the hands is uncommon, accounting for
0.1% of all bone metastases [1]. Healey et al. reported that
most acrometastases involve the dominant hand, as seen in
this patient, being the one that receives a larger quantity of
blood and possibly the one more likely to be injured than
the non-dominant hand [2]. It has been suggested that
prostaglandins released following trauma may be responsi-
ble for cell migration and adherence to osseous material
[3]. The radiological differential diagnosis of an expansile
lytic lesion in the hand include metastases from renal cell
carcinoma and thyroid malignancy, giant cell tumor and
enchondroma with the latter two occurring in the younger
age group.
Metastases to hand bones generally indicate very advanced
primary tumors with an average survival of six months [4].
Palliative amputation was the preferred treatment in the
reported cases [5]. The PET/CT scan of this patient showed
only a single distant metastasis to her hand and thus herprognosis is expected to be better. A curative approach with
complete resection of the primary tumor and oligometastastic
site in stage IV non-small cell lung carcinoma (NSCLC) followed
by cytotoxic chemotherapy has not been reported to date. It is
unclear whether such an approach results in a similar outcome
as NSCLC with solitary brain, lung or adrenal metastasis. In the
SELECT (Surgically resected EGFR-mutant Lung cancer with
adjuvant Erlotinib Cancer Treatment) multicenter prospective
phase II trial, patients with resected stage IA to IIIA NSCLC
harboring a TKI-sensitizing EGFR mutation and treated with
erlotinib 150 mg daily for 2 years after completion of standard
adjuvant chemotherapy and/or radiotherapy had a 2-year
disease-free survival of 90% (with a median follow-up of 3 years)
compared to a historical control of 76% in resected early-stage
EGFR-mutant NSCLC [6].4. Conclusion
In the case of EGFR-mutant lung adenocarcinoma with
oligometastasis involving the metacarpal bone, complete
resection of the primary lung tumor with amputation or
Fig. 3 Computed tomography of the thorax shows a right
upper lobe lung mass.
23Acrometastasis from an epidermal-growth-factor-receptor (EGFR) mutation-positive lung adenocarcinomawide excision of the affected ﬁnger should be considered
followed by platinum doublet chemotherapy or EGFR TKI
treatment. Such an approach has not been reported to date
and the outcome including disease-free survival is still
unclear.
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